Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend and
enhance the lives of patients with cancer and other severe medical conditions.
Our lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in
Phase 3 development for non-small cell lung cancer (NSCLC) and in a broad
development program including clinical trials for breast cancer, ovarian cancer
and acute myeloid leukemia (AML). In addition, we are developing a unique,
proprietary platform for enhanced delivery of anti-cancer drugs directly to
tumor cells, known as Hsp90-inhibitor drug conjugates (HDCs). All of our drug
candidates were invented by Synta scientists and are fully owned by Synta.
In 2013, we made significant progress in expanding the breadth of the
ganetespib development program and developing our HDC platform.